EGFR and head and neck squamous cell carcinoma: Of note, most HNSCCs show overexpression of EGFR, but never activating point mutations, which may explain the lack of response to EGFR-targeting kinase inhibitors such as gefitinib and erlotinib [4,66], suggesting that HNSCC cells might not be addicted to EGFR.